Keyword Index

Browse for an article via relevant keywords across our entire electronic archive

Search results for: Z
Results 1 - 10 of 22 shown below

  • ZD 1839

    J M Sewell, K G Macleod, A Ritchie, J F Smyth and S P Langdon

    Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa')

    doi:10.1038/sj.bjc.6600058

    Abstract | Full article | PDF

  • F Cappuzzo, C Calandri, S Bartolini and L Crinò

    ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases

    doi:10.1038/sj.bjc.6601116

    Abstract | Full article | PDF

  • F Barlési, C Tchouhadjian, C Doddoli, J-P Torre, P Astoul and J-P Kleisbauer

    CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

    advance online publication, 2004-12-14 00:00:00.000;

    doi:10.1038/sj.bjc.6602296

    Abstract | Full article | PDF

  • ZD0473

    J Cosaert and E Quoix

    Platinum drugs in the treatment of non-small-cell lung cancer

    doi:10.1038/sj.bjc.6600540

    Abstract | Full article | PDF

  • ZD1839

    N Magné, J L Fischel, A Dubreuil, P Formento, S Marcié, J-L Lagrange and G Milano

    Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer

    doi:10.1038/sj.bjc.6600103

    Abstract | Full article | PDF

  • K J Williams, B A Telfer, I J Stratford and S R Wedge

    ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model

    doi:10.1038/sj.bjc.6600182

    Abstract | Full article | PDF

  • N Magné, J L Fischel, A Dubreuil, P Formento, M-F Poupon, P Laurent-Puig and G Milano

    Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa')

    doi:10.1038/sj.bjc.6600299

    Abstract | Full article | PDF

  • N Magné, J-L Fischel, C Tiffon, P Formento, A Dubreuil, N Renée, J-L Formento, M Francoual, J Ciccolini, M-C Etienne and G Milano

    Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil

    doi:10.1038/sj.bjc.6601131

    Abstract | Full article | PDF

  • S B Maddineni, V K Sangar, J H Hendry, G P Margison and N W Clarke

    Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines

    advance online publication, 2004-12-21 00:00:00.000;

    doi:10.1038/sj.bjc.6602299

    Abstract | Full article | PDF

  • G Lorch, J L Gilmore, P F Koltz, R M Gonterman, R Laughner, D A Lewis, R L Konger, K S Nadella, R E Toribio, T J Rosol and J Foley

    Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice

    advance online publication, 2007-05-29 00:00:00.000;

    doi:10.1038/sj.bjc.6603828

    Abstract | Full article | PDF

  • ZD2767

    N R Monks, J A Calvete, N J Curtin, D C Blakey, S J East and D R Newell

    Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

    doi:10.1054/bjoc.2000.1240

    Abstract | Full article | PDF

  • N R Monks, D C Blakey, N J Curtin, S J East, A Heuze and D R Newell

    Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

    doi:10.1054/bjoc.2001.1947

    Abstract | Full article | PDF

  • ZD4054

    C D Morris, A Rose, J Curwen, A M Hughes, D J Wilson and D J Webb

    Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence

    doi:10.1038/sj.bjc.6602676

    Abstract | Full article | PDF

  • ZD6126

    S P Robinson, D J O McIntyre, D Checkley, J J Tessier, F A Howe, J R Griffiths, S E Ashton, A J Ryan, D C Blakey and J C Waterton

    Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

    doi:10.1038/sj.bjc.6600926

    Abstract | Full article | PDF

  • A Bozec, S Lassalle, J Gugenheim, J-L Fischel, P Formento, P Hofman and G Milano

    Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126

    advance online publication, 2006-08-29 00:00:00.000;

    doi:10.1038/sj.bjc.6603308

    Abstract | Full article | PDF

  • M Martinelli, K Bonezzi, E Riccardi, E Kuhn, R Frapolli, M Zucchetti, A J Ryan, G Taraboletti and R Giavazzi

    Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel

    advance online publication, 2007-09-11 00:00:00.000;

    doi:10.1038/sj.bjc.6603969

    Abstract | Full article | PDF

  • ZD6474

    A J Ryan and S R Wedge

    ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

    doi:10.1038/sj.bjc.6602603

    Abstract | Full article | PDF

  • J V Heymach

    ZD6474 – clinical experience to date

    doi:10.1038/sj.bjc.6602604

    Abstract | Full article | PDF

  • Y Mi and L Lou

    ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein

    advance online publication, 2007-10-02 00:00:00.000;

    doi:10.1038/sj.bjc.6603985

    Abstract | Full article | PDF

  • ZD9331

    S D Webley, S J Welsh, A L Jackman and G W Aherne

    The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition

    doi:10.1054/bjoc.2001.1921

    Abstract | Full article | PDF

  • zearalenone

    L Hilakivi-Clarke, I Onojafe, M Raygada, E Cho, T Skaar, I Russo and R Clarke

    Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis

    doi:10.1038/sj.bjc.6690584

    Abstract | Full article | PDF

  • Zemplar

    N Dunlap, G G Schwartz, D Eads, S D Cramer, A B Sherk, V John and C Koumenis

    1alpha,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1alpha,25(OH)2D2, potentiate the effects of ionising radiation on human prostate cancer cells

    doi:10.1038/sj.bjc.6601161

    Abstract | Full article | PDF